アデノ随伴ウイルスベクター製造の市場規模、シェア、動向分析レポート：事業規模別、方法別、治療領域別、用途別、地域別、セグメント別予測、2025年～2030年

アデノ随伴ウイルスベクター製造市場の成長と動向：

Grand View Research, Incの最新レポートによると、世界のアデノ随伴ウイルスベクター製造市場規模は、2025年から2030年にかけて18.55％のCAGRを記録し、2030年までに27億8,000万米ドルに達すると予測されています。

この成長は、がん、嚢胞性線維症、デュシェンヌ型筋ジストロフィー、網膜色素変性症などの慢性疾患の有病率の増加に起因しています。アデノ随伴ウイルス（AAV）ベクターは、これらの疾患の治療において重要な役割を果たしています。また、AAVベクターは遺伝子治療のデリバリーにも幅広く応用されています。各社は、研究開発の進展に伴う革新的な製品の上市に向けて、共同研究、合併、提携に取り組んでいます。

例えば、2021年12月、アステラス製薬とDyno Therapeuticsは、DynoのCapsidMapプラットフォームを用いた遺伝子治療用NGSベースAAVベクターの心臓および骨格筋への開発に関する戦略的提携を締結しました。このような取り組みにより、抗体の開発・生産における市場でのプレゼンス拡大が期待され、市場の成長を支えるものと思われます。COVID-19パンデミックは業界に好影響を与えました。アデノ随伴ウイルスはワクチン製造に膨大な用途があるため、さまざまな企業がCOVID-19を治療するワクチンの製造競争に参加しました。その結果、これらのベクターの製造需要が急増しました。

例えば、2021年9月、CEVECとUCBは、研究開発および遺伝子治療用途にELEVECTA AAVベクター製造技術を使用するための戦略的契約を締結しました。遺伝子治療は遺伝子の改変を伴うため、多くの倫理的問題があります。その結果、米国政府は生殖細胞系列遺伝子治療の研究に対する連邦資金の使用を制限しました。遺伝子治療は、家族の将来の世代を特定の遺伝性疾患の発症から救うのに役立ちます。しかし、胎児の発育に大きな影響を与えることが予想されます。ワクチン、遺伝子治療薬、CGMP医薬品、急性疾患を治療・治癒するための製品に対する高い需要や、患者ケアの改善に対する需要も、業界の成長を後押ししています。したがって、世界の利害関係者は、増大する需要を満たすために生産能力を拡大するために多額の投資を行っています。

アデノ随伴ウイルスベクター製造市場レポートハイライト

• 事業規模別では、2024年に商業セグメントが業界を支配しました。企業による研究開発投資の増加とワクチンメーカーからの需要による。
• 神経疾患治療領域セグメントは、慢性神経変性疾患の高い有病率と、これらの疾患を治療するためのアデノ随伴ウイルスベクターベースの療法の有効性により、2024年に最大のシェアを獲得しました。
• ワクチンは主要な応用分野と考えられており、2024年に最大の収益シェアを占め、ワクチン治療薬に対する需要の高まりとワクチン製造のための投資と資金の増加により、予測期間を通じて支配的な地位を維持する可能性が高いです。
• 北米は強力な地域地位を確立しています。がん罹患率の増加と研究開発費の高騰が、同地域の企業による製品開発を後押しし、同地域市場を牽引しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助市場見通し
• 市場動向と展望
  • 市場力学
  • 市場抑制要因分析
• ビジネス環境分析
  • SWOT分析;要因別（政治・法律、経済・技術）
  • ポーターのファイブフォース分析
  • COVID-19の影響分析

第4章 事業規模のビジネス分析

• 事業規模セグメントダッシュボード
• 世界のアデノ随伴ウイルスベクター製造市場：事業規模の変動分析
• 世界のアデノ随伴ウイルスベクター製造市場の規模と動向分析、事業規模別、2018～2030年
• 臨床
  • 臨床市場、2018年-2030年
• 前臨床
  • 前臨床市場、2018年-2030年
• 商業
  • 商業市場、2018年-2030年

第5章 ビジネス分析の方法

• メソッドセグメントダッシュボード
• 世界のアデノ随伴ウイルスベクター製造市場：方法変動分析
• 世界のアデノ随伴ウイルスベクター製造市場の規模と動向分析、方法別、2018～2030年
• In Vitro
  • In Vitro 市場、2018年-2030年
• In Vivo
  • In Vivo市場、2018年-2030年

第6章 治療領域のビジネス分析

• 治療領域セグメントダッシュボード
• 世界のアデノ随伴ウイルスベクター製造市場：治療領域変動分析
• 世界のアデノ随伴ウイルスベクター製造市場規模と動向分析、治療領域別、2018～2030年
• 血液疾患
  • 血液疾患市場、2018年-2030年
• 感染症
  • 感染症市場、2018年-2030年
• 遺伝性疾患
  • 遺伝性疾患市場、2018年-2030年
• 神経疾患
  • 神経疾患市場、2018年-2030年
• 眼疾患
  • 眼科疾患市場、2018年-2030年
• その他
  • その他市場、2018年-2030年

第7章 用途ビジネス分析

• 用途セグメントダッシュボード
• 世界のアデノ随伴ウイルスベクター製造市場：用途変動分析
• 世界のアデノ随伴ウイルスベクター製造市場規模と動向分析、用途別、2018～2030年
• 細胞治療
  • 細胞治療市場、2018年-2030年
• 遺伝子治療
  • 遺伝子治療市場、2018年-2030年
• ワクチン
  • ワクチン市場、2018年-2030年

第8章 地域ビジネス分析

• 地域ダッシュボード
• 市場規模と予測および動向分析、2018年から2030年
• 北米
  • 北米のアデノ随伴ウイルスベクター製造市場、2018年-2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州のアデノ随伴ウイルスベクター製造市場、2018年-2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋地域のアデノ随伴ウイルスベクター製造市場、2018年-2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカのアデノ随伴ウイルスベクター製造市場、2018年-2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカアデノ随伴ウイルスベクター製造市場、2018-2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参入企業
• 戦略マッピング
• 企業市況分析、2024年
• 参入企業の概要
  • F. Hoffmann-La Roche Ltd
  • Charles River Laboratories
  • Oxford Biomedica PLC
  • WuXi AppTec
  • Yposkesi, Inc.
  • Sarepta Therapeutics, Inc.
  • Pfizer Inc.
  • Genezen
  • Creative Biogene
  • GenScript（ProBio）

List of Tables

• Table 1 List of secondary sources
• Table 2 Global adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 3 Global adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 4 Global adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 5 Global adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 6 Global adeno associated virus vector manufacturing market, by region, 2018 - 2030 (USD Million)
• Table 7 North America adeno associated virus vector manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 8 North America adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 9 North America adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 10 North America adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 11 North America adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 12 U.S. adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 13 U.S. adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 14 U.S. adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 15 U.S. adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 16 Canada adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 17 Canada adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 18 Canada adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 19 Canada adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 20 Mexico adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 21 Mexico adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 22 Mexico adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 23 Mexico adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 24 Europe adeno associated virus vector manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 25 Europe adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 26 Europe adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 27 Europe adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 28 Europe adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 29 UK adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 30 Europe adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 31 UK adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 32 UK adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 33 Germany adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 34 Germany adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 35 Germany adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 36 Germany adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 37 France adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 38 France adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 39 France adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 40 France adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 41 Italy adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 42 Italy adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 43 Italy adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 44 Italy adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 45 Spain adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 46 Spain adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 47 Spain adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 48 Spain adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 49 Denmark adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 50 Denmark adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 51 Denmark adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 52 Denmark adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 53 Sweden adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 54 Sweden adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 55 Sweden adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 56 Sweden adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 57 Norway adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 58 Norway adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 59 Norway adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 60 Norway adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific adeno associated virus vector manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 66 Japan adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 67 Japan adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 68 Japan adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 69 Japan adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 70 China adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 71 China adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 72 China adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 73 China adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 74 India adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 75 India adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 76 India adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 77 India adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 78 Australia adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 79 Australia adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 80 Australia adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 81 Australia adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 82 Thailand adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 83 Thailand adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 84 Thailand adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 85 Thailand adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 86 South Korea adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 87 South Korea adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 88 South Korea adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 89 South Korea adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 90 Latin America adeno associated virus vector manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 91 Latin America adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 92 Latin America adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 93 Latin America adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 94 Latin America adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 95 Brazil adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 96 Brazil adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 97 Brazil adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 98 Brazil adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 99 Argentina adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 100 Argentina adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 101 Argentina adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 102 Argentina adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 103 Middle East and Africa adeno associated virus vector manufacturing market, by country, 2018 - 2030 (USD Million)
• Table 104 Middle East and Africa adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 105 Middle East and Africa adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 106 Middle East and Africa adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 107 Middle East and Africa adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 108 South Africa adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 109 South Africa adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 110 South Africa adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 111 South Africa adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 116 UAE adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 117 UAE adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 118 UAE adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 119 UAE adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)
• Table 120 Kuwait adeno associated virus vector manufacturing market, by scale of operations, 2018 - 2030 (USD Million)
• Table 121 Kuwait adeno associated virus vector manufacturing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 122 Kuwait adeno associated virus vector manufacturing market, by application, 2018 - 2030 (USD Million)
• Table 123 Kuwait adeno associated virus vector manufacturing market, by method, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Adeno associated virus vector manufacturing market segmentation
• Fig. 8 Market snapshot
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 Market challenge relevance analysis (current & future impact)
• Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 14 Porter's five forces analysis
• Fig. 15 Global adeno associated virus vector manufacturing market: mode movement analysis
• Fig. 16 Global adeno associated virus vector manufacturing market, for in vitro, 2018 - 2030 (USD Million)
• Fig. 17 Global adeno associated virus vector manufacturing market, for in vivo, 2018 - 2030 (USD Million)
• Fig. 18 Global adeno associated virus vector manufacturing market: scale of operations movement analysis
• Fig. 19 Global adeno associated virus vector manufacturing market, for clinical, 2018 - 2030 (USD Million)
• Fig. 20 Global adeno associated virus vector manufacturing market, for preclinical, 2018 - 2030 (USD Million)
• Fig. 21 Global adeno associated virus vector manufacturing market, for commercial, 2018 - 2030 (USD Million)
• Fig. 22 Global adeno associated virus vector manufacturing market: therapeutic area movement analysis
• Fig. 23 Global adeno associated virus vector manufacturing market, for haematological diseases, 2018 - 2030 (USD Million)
• Fig. 24 Global adeno associated virus vector manufacturing market, for infectious diseases, 2018 - 2030 (USD Million)
• Fig. 25 Global adeno associated virus vector manufacturing market, for genetic disorders, 2018 - 2030 (USD Million)
• Fig. 26 Global adeno associated virus vector manufacturing market, for neurological disorders, 2018 - 2030 (USD Million)
• Fig. 27 Global adeno associated virus vector manufacturing market, for ophthalmic disorders, 2018 - 2030 (USD Million)
• Fig. 28 Global adeno associated virus vector manufacturing market, for others, 2018 - 2030 (USD Million)
• Fig. 29 Global adeno associated virus vector manufacturing market: application movement analysis
• Fig. 30 Global adeno associated virus vector manufacturing market, for cell therapy, 2018 - 2030 (USD Million)
• Fig. 31 Global adeno associated virus vector manufacturing market, for gene therapy, 2018 - 2030 (USD Million)
• Fig. 32 Global adeno associated virus vector manufacturing market, for vaccine, 2018 - 2030 (USD Million)
• Fig. 33 Regional marketplace: Key takeaways
• Fig. 34 Regional outlook, 2024 & 2030
• Fig. 35 Global adeno associated virus vector manufacturing market: region movement analysis
• Fig. 36 North America adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 37 U.S. Adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 38 Canada adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 39 Mexico adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 40 Europe adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 41 Germany adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 42 UK adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 43 France adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 44 Italy adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 45 Spain adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 46 Denmark adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 47 Sweden adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 48 Norway adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 49 Asia pacific adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 50 Japan adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 51 China adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 52 India adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 53 Australia adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 54 South Korea adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 55 Thailand adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 56 Latin America adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 57 Brazil adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 58 Argentina adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 59 Middle East and Africa adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 60 South Africa adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 61 Saudi Arabia adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 62 UAE adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)
• Fig. 63 Kuwait adeno associated virus vector manufacturing market, 2018 - 2030 (USD Million)

Adeno Associated Virus Vector Manufacturing Market Growth & Trends:

The global adeno associated virus vector manufacturing market size is expected to reach USD 2.78 billion by 2030, registering a CAGR of 18.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to the increasing prevalence of chronic diseases like cancers, cystic fibrosis, Duchenne muscular dystrophy, retinitis pigmentosa, and many more. Adeno-associated virus (AAV) vector plays a vital role in the treatment of these diseases. AAV vectors also have a wide range of applications in gene therapy delivery. Companies are engaged in collaborations, mergers, and partnerships for innovative product launches with advancements in R&D.

For instance, in December 2021, Astellas and Dyno Therapeutics entered into a strategic collaboration to develop an NGS-based AAV vector for gene therapy by using Dyno's CapsidMap platform for cardiac and skeletal muscle. Such initiatives are expected to expand their market presence in the development and production of antibodies, which is likely to support the growth of the market. The COVID-19 pandemic had a positive impact on the industry. As adeno associated virus has vast applications in vaccine manufacturing, various companies were involved in the race to manufacture the vaccine to treat COVID-19. This resulted in a sudden spur in the demand for manufacturing these vectors.

For instance, in September 2021, CEVEC and UCB entered into a strategic agreement for the use of ELEVECTA AAV vector manufacturing technology for R&D and gene therapy applications. As gene therapy involves alterations or modifications in the set of genes, it has raised many ethical issues. As a result, the U.S. government restricted the usage of federal funds for research on germline gene therapy in people. Gene therapy can help save future generations of a family from acquiring a particular genetic disorder. However, it is anticipated to affect the fetus's development significantly. The high demand for vaccines, gene therapeutics, CGMP drugs, and products to treat & cure acute diseases and the demand for improving patient care also propel the industry growth. Thus, global stakeholders are investing significantly in expanding their production capacities to fulfill the growing demands.

Adeno Associated Virus Vector Manufacturing Market Report Highlights:

• By the scale of operations, the commercial segment dominated the industry in 2024. Owing to the increasing R&D investment by companies and demand from vaccine manufacturers
• The neurological diseases therapeutic area segment captured the largest share in 2024 due to the high prevalence of chronic neurodegenerative diseases and the effectiveness of the adeno associated virus vector-based therapies to treat these diseases
• Vaccine is considered a key application segment, which held the largest revenue share in 2024 and is likely to remain dominant throughout the forecast period due to the rising demand for vaccine therapeutics and increasing investments & funds for the production of vaccines
• North America has established a strong regional position. The increasing incidence of cancer and high R&D expenditure is encouraging companies in the region to undertake product development, which drives the regional market

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Scale of Operations
  • 1.2.2. Method
  • 1.2.3. Therapeutic Area
  • 1.2.4. Application
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
  • 3.2.1. Market Dynamics
    • 3.2.1.1. Technological advancements in manufacturing vectors
    • 3.2.1.2. Robust pipelines for gene therapies and vaccines
    • 3.2.1.3. Increasing number of emerging players
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory, scientific and ethical challenges
    • 3.2.2.2. Production capacity challenges
• 3.3. Business Environment Analysis
  • 3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.3.2. Porter's Five Forces Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Scale Of Operations Business Analysis

• 4.1. Scale of Operations Segment Dashboard
• 4.2. Global Adeno Associated Virus Vector Manufacturing Market: Scale of Operations Movement Analysis
• 4.3. Global Adeno Associated Virus Vector Manufacturing Market Size & Trend Analysis, by Scale of Operations, 2018 to 2030 (USD Million)
• 4.4. Clinical
  • 4.4.1. Clinical Market, 2018 - 2030 (USD Million)
• 4.5. Preclinical
  • 4.5.1. Preclinical Market, 2018 - 2030 (USD Million)
• 4.6. Commercial
  • 4.6.1. Commercial Market, 2018 - 2030 (USD Million)

Chapter 5. Method Business Analysis

• 5.1. Method Segment Dashboard
• 5.2. Global Adeno Associated Virus Vector Manufacturing Market: Method Movement Analysis
• 5.3. Global Adeno Associated Virus Vector Manufacturing Market Size & Trend Analysis, by Method, 2018 to 2030 (USD Million)
• 5.4. In Vitro
  • 5.4.1. In Vitro Market, 2018 - 2030 (USD Million)
• 5.5. In Vivo
  • 5.5.1. In Vivo Market, 2018 - 2030 (USD Million)

Chapter 6. Therapeutic Area Business Analysis

• 6.1. Therapeutic Area Segment Dashboard
• 6.2. Global Adeno Associated Virus Vector Manufacturing Market: Therapeutic Area Movement Analysis
• 6.3. Global Adeno Associated Virus Vector Manufacturing Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 6.4. Hematological Diseases
  • 6.4.1. Hematological Diseases Market, 2018 - 2030 (USD Million)
• 6.5. Infectious Diseases
  • 6.5.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
• 6.6. Genetic Disorders
  • 6.6.1. Genetic Disorders Market, 2018 - 2030 (USD Million)
• 6.7. Neurological Disorders
  • 6.7.1. Neurological Disorders Market, 2018 - 2030 (USD Million)
• 6.8. Ophthalmic Disorders
  • 6.8.1. Ophthalmic Disorders Market, 2018 - 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Application Segment Dashboard
• 7.2. Global Adeno Associated Virus Vector Manufacturing Market: Application Movement Analysis
• 7.3. Global Adeno Associated Virus Vector Manufacturing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 7.4. Cell Therapy
  • 7.4.1. Cell Therapy Market, 2018 - 2030 (USD Million)
• 7.5. Gene Therapy
  • 7.5.1. Gene Therapy Market, 2018 - 2030 (USD Million)
• 7.6. Vaccine
  • 7.6.1. Vaccine Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. North America Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. U.S. Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Canada Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Mexico Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Germany Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.3. UK
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. UK Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. France Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Italy Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Spain Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Denmark Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Sweden Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Target Disease Prevalence
    • 8.4.9.3. Competitive Scenario
    • 8.4.9.4. Regulatory Framework
    • 8.4.9.5. Norway Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Japan Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. China Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. India Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Competitive Scenario
    • 8.5.5.4. Regulatory Framework
    • 8.5.5.5. South Korea Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.6. Australia
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Competitive Scenario
    • 8.5.6.4. Regulatory Framework
    • 8.5.6.5. Australia Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Competitive Scenario
    • 8.5.7.4. Regulatory Framework
    • 8.5.7.5. Thailand Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Brazil Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Argentina Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Competitive Scenario
    • 8.7.2.4. Regulatory Framework
    • 8.7.2.5. South Africa Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Competitive Scenario
    • 8.7.3.4. Regulatory Framework
    • 8.7.3.5. Saudi Arabia Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Target Disease Prevalence
    • 8.7.4.3. Competitive Scenario
    • 8.7.4.4. Regulatory Framework
    • 8.7.4.5. UAE Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Target Disease Prevalence
    • 8.7.5.3. Competitive Scenario
    • 8.7.5.4. Regulatory Framework
    • 8.7.5.5. Kuwait Adeno Associated Virus Vector Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Participant's Overview
  • 9.4.1. F. Hoffmann-La Roche Ltd
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Service Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Charles River Laboratories
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Service Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Oxford Biomedica PLC
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Service Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. WuXi AppTec
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Service Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Yposkesi, Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Service Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Sarepta Therapeutics, Inc.
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Service Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Pfizer Inc.
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Service Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Genezen
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Service Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Creative Biogene
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Service Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. GenScript (ProBio)
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Service Benchmarking
    • 9.4.10.4. Strategic Initiatives